Conference
A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies.
Abstract
2542
Authors
Langleben A; Supko JG; Hotte SJ; Batist G; Hirte HW; Rogoff H; Li Y; Li W; Kerstein D; Leggett D
Volume
31
Pagination
pp. 2542-2542
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2013
DOI
10.1200/jco.2013.31.15_suppl.2542
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X